Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Howmet Aerospace Inc (HWM) vs Merck & Co., Inc. (MRK) Price & Performance

Howmet Aerospace IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Howmet Aerospace Inc vs Merck & Co., Inc. — how do they compare? Howmet Aerospace Inc trades at $282.65 (market cap $112.20B), while Merck & Co., Inc. trades at $132.99 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 2.9× Howmet Aerospace Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

HWMMRK
Market Cap
$112.20B$321.77B
Sector
IndustrialsHealth
52-Week High
$291.28$131.84
52-Week Low
$171.00$77.60
Enterprise Value
$116.30B$368.53B
Dividend Yield
0.2%2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Howmet Aerospace Inc

Howmet Aerospace (HWM) trades at $281.63, down 0.73% on the day, with strong technical support at $279 and resistance at $285. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $1.33 exceeding expectations by 7.3%, driven by robust aerospace and defense demand. Analyst consensus remains strongly bullish with 84% buy ratings and a $334.63 price target, representing 19% upside potential.

Outlook remains positive with raised 2026 guidance and strong cash flow generation, though elevated valuation multiples (P/E 60.63) and significant capital expenditures present risks. The stock offers growth exposure to aerospace recovery but faces execution risks amid capacity expansion plans and supply chain challenges.

Merck & Co., Inc.

Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.

The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Howmet Aerospace Inc

Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.

Read more on HWM

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK